No clear answer
Laquinimod: protect nerve tissue in relapsing MS
relapsing MS · T-cell co-stimulation / cytokine targeting
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
Laquinimod was refused in the EU. A positive trial result does not mean the medicine is available.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 1
These linked trials do not set the status.
- LIBRETTOStopped, other reason
Phase 3 · 2014 · Compared with interferon beta-1a
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as No clear answer
Related hypotheses
- Laquinimod: protect nerve tissue in primary progressive MS
- Abatacept: reduce relapses and new lesions in relapsing MS
- Daclizumab: reduce relapses and new lesions in relapsing MS
- Dapirolizumab pegol: reduce relapses and new lesions in relapsing MS
- Frexalimab: reduce relapses and new lesions in relapsing MS
- Secukinumab: reduce relapses and new lesions in relapsing MS
- Ustekinumab: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error